Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.

2.50
Hdl Handle:
http://hdl.handle.net/10147/233251
Title:
Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.
Authors:
Shireen, R; Brennan, D; Flannelly, G; Fennelly, D; Lenehan, P; Foley, M
Affiliation:
Department of Obstetrics, National Maternity Hospital, Holles St., Dublin 2.
Citation:
Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. 2012, 105 (2):47-50 Ir Med J
Publisher:
Irish Medical Journal (IMJ)
Journal:
Irish medical journal
Issue Date:
Feb-2012
URI:
http://hdl.handle.net/10147/233251
PubMed ID:
22455239
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed?term=Survival%20in%20Women%20with%20Ovarian%20Cancer%20Before%20and%20After%20the%20Introduction%20of%20Adjuvant%20Paclitaxel%3B%20A%2025-Year%2C%20Single%20Institution%20Review
Abstract:
Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.
Item Type:
Article
Language:
en
MeSH:
Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel
ISSN:
0332-3102

Full metadata record

DC FieldValue Language
dc.contributor.authorShireen, Ren_GB
dc.contributor.authorBrennan, Den_GB
dc.contributor.authorFlannelly, Gen_GB
dc.contributor.authorFennelly, Den_GB
dc.contributor.authorLenehan, Pen_GB
dc.contributor.authorFoley, Men_GB
dc.date.accessioned2012-07-11T14:57:23Z-
dc.date.available2012-07-11T14:57:23Z-
dc.date.issued2012-02-
dc.identifier.citationSurvival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. 2012, 105 (2):47-50 Ir Med Jen_GB
dc.identifier.issn0332-3102-
dc.identifier.pmid22455239-
dc.identifier.urihttp://hdl.handle.net/10147/233251-
dc.description.abstractAdjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journal (IMJ)en_GB
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed?term=Survival%20in%20Women%20with%20Ovarian%20Cancer%20Before%20and%20After%20the%20Introduction%20of%20Adjuvant%20Paclitaxel%3B%20A%2025-Year%2C%20Single%20Institution%20Reviewen_GB
dc.rightsArchived with thanks to Irish medical journalen_GB
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdenocarcinoma, Mucinous-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCystadenocarcinoma, Serous-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasm, Residual-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPaclitaxel-
dc.titleSurvival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Obstetrics, National Maternity Hospital, Holles St., Dublin 2.en_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.